Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.
Harding
M J
MJ
Department of Medical Oncology, University of Glasgow, UK.
Cantwell
B M
BM
Milstead
R A
RA
Harris
A L
AL
Kaye
S B
SB
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005492:Folic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D011799:Quinazolines; C031662:CB 3717; D005492:Folic Acid